**Instructions for Authors 2016**

**General Policy.** ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrantee due diligence in the creation and issuance of their work.

**NIH Open Access Policy.** The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

**Copyright.** Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

**Format.** Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

**Manuscripts.** Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

- (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

**Figures.** All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges.

**Tables.** All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXX (where XXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: http://www.iiar-submissions.com/login.html

In case a submission is incomplete, the corresponding Author will be notified accordingly.

Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online annual subscription to Anticancer Research for the current year. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Specific information and additional instructions for Authors

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.

2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees. (For further information please click here)

3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.

4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal's secretary, the reviewers and the printers.
5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.

6. Authors should pay attention to the following points when writing an article for AR:
- The Instructions to Authors must be followed in every detail.
- The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
- The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
- Results given in figures should not be repeated in tables.
- Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
- Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
- Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
- Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
- Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
- The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
- By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.

7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.

8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc.
   Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).

9. Articles submitted to AR may be rejected without review if:
- they do not fall within the journal's policy.
- they do not follow the instructions to authors.
- language is unclear.
- results are not sufficient to support a final conclusion.
- results are not objectively based on valid experiments.
- they repeat results already published by the same or other authors before the submission to AR.
- plagiarism is detected by plagiarism screening services.
   (Rejection rate (2015): 64%).

10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.

11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org

12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.

13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.
   (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Copyright© 2016 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
**General Policy**

- **IN VIVO** is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of **IN VIVO** is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- **IN VIVO** supports: (a) the aims and the research program of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH. The IIAR is a member of UICC.

**Editorial Office**

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

E-mail: journals@iiar-anticancer.org; IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

**Selection of Recent Articles**


Effects of Targeted Proton Radiation on Spinal Cord in a Porcine Model: A Pilot Study. X.W. MAO, M.J. PECAUT, J.D. CAO, D.S. GRIDLEY (Loma Linda, CA, USA)


Radical-scavenging and Anti-inflammatory Activity of Quercetin and Related Compounds and Their Combinations Against RAW264.7 Cells Stimulated with Porphyromonas gingivalis Fimbriae. Relationships between Anti-inflammatory Activity and Quantum Chemical Parameters. Y. MURAKAMI, A. KAWATA, S. ITO, T. KATAYAMA, S. FUJISAWA (Sakado, Saitama; Tokyo, Japan)


Management of Very Early-onset Fetal Growth Restriction: Results from 92 Consecutive Cases. F. HOELLEN, A. BECKMANN, C. BANZ-JANSEN, J. WEICHERT, A. RODY, M.K. BOHLMANN (Lübeck; Mannheim, Germany)

Implementation of a Functional Observation Battery for the Assessment of Postoperative Well being in Rats Subjected to Fimbria-Fornix Transection. L. MARSCHEINER, E. WOGENSEN, J. MOGENSEN, K. ABELESON (Copenhagen, Denmark)

Decreased Numbers of CD57+CD3- Cells Identify Potential Inmate Immune Differences in Patients with Autism Spectrum Disorder. D. SINISCALCO, T. MJATOVIC, E. BOSMANS, A. CIRILLO, P. KRUZLIK, V.C. LOMBARDI, K. DE MEIRLEIR, N. ANTONUCCI (Naples; Caserta; Florence; Bari, Italy; Zellik; Brussels, Belgium; Brno, Czech Republic; Reno, NV, USA)


PEO-generated Surfaces Support Attachment and Growth of Cells In Vitro with No Additional Benefit for Micro-roughness in Sa (0.2-4 μm). O. JUNG, R. SMEETS, A. KOPP, D. PORCHETTA, P. HIESTER, M. HEILAND, R.E. FRIEDICH, C. PRECHT, H. HANKEN, A. GRÖBE, P. HARTJEN (Hamburg; Aachen, Germany)


Suppressive Activity of Quercetin on Periostin Functions In Vitro. S. IRIE, M. KASHIWARABARA, A. YAMADA, K. ASANO (Yokohama, Japan)

The Prolonged QT Interval: Role of Pro-inflammatory Cytokines, Reactive Oxygen Species and the Ceramide and Sphingosine-1 Phosphate Pathways. P.P. SORDILLO, D.C. SORDILLO, L. HELSON (Quakertown, PA, USA)

Specific Antibodies to Staphylococcus aureus Biofilm Are Present in Serum from Pigs with Osteomyelitis. L.K. JENSEN, H.E. JENSEN, J. KOCH, T. BJARNHOLST, S. EICKHARDT, M. SHIRTLIFF (Copenhagen, Denmark; Baltimore, MD, USA)

**FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST**

Methylation of the ER-alpha Promoter Is Influenced by its Ligand Estrogen in Osteosarcoma Cells SAOS-2 In Vitro. J. TÜBEL, L. KUNTZ, C. MARTHEN, A. SCHMITT, I. WIEST, R. VON EISENHART-ROTHE, U. JESCHKE, R. BURGKART (Munich, Germany) .......................................................................................................................................................................................... 3199


Book Reviews .......................................................................................................................................................................................... 3223

Announcements .......................................................................................................................................................................................... 3227

Expression of the Insulin-like Growth Factor-1 Receptor in Odontogenic Myxoma. R.E. FRIEDRICH, C. HAGEL, J. ZUSTIN (Hamburg, Germany; London, UK) .................................................................................................................. 3103

Cherubism: A Case Report with Surgical Intervention. R.E. FRIEDRICH, H.A. SCHEUER, J. ZUSTIN, T. GROB (Hamburg; Münster, Germany) ........................................................................................................... 3109


Determination of Interleukin-4, -5, -6, -8 and -13 in Serum of Patients with Breast Cancer Before Treatment and its Correlation to Circulating Tumor Cells. A. KÖNIG, T. VILSMAIER, B. RACK, K. FRIESE, W. JANNI, U. JESCHKE, U. ANDERGASSEN, E. TRAPP, J. JÜCKSTOCK, B. JÄGER, M. ALUNNI-FABBRONI, T. FRIEDL, T. WEISSENBACHER (Munich; Ulm, Germany) .................................................................................................................. 3123


FOXP3+ Cells Recruited by CCL22 into Breast Cancer Correlates with Less Tumor Nodal Infiltration. C.P. FREIER, C. KUHN, S. ENDRES, D. MAYR, K. FRIESE, U. JESCHKE, D. ANZ (Munich, Germany) ....... 3139

Effect of BSA-coated Superparamagnetic Iron Oxide Nanoparticles on Granulosa Cells. M. POETTLER, S. HOFMANN, S. DÜRR, H. UNTERWEGER, I. WIEST, J. ZALOGA, C. ALEXIOU, U. JESCHKE, C. JANKO (Erlangen; Munich, Germany) .................................................................................................................. 3147

Recurrent Maxillary Odontogenic Myxoma Following Partial Maxillary Resection and Consecutive Osseous Reconstruction Including Tooth Transplantation. R.E. FRIEDRICH, H.A. SCHEUER, W. HÖLTJE (Hamburg, Germany) .................................................................................................................. 3155

Expansive Extracranial Growth of Intracranial Meningioma in Neurofibromatosis Type 2. R.E. FRIEDRICH, C. HAGEL (Hamburg, Germany) .................................................................................................................. 3161

Mucoepidermoid Carcinoma - Unknown Primary Affecting the Neck. R.E. FRIEDRICH, J. ZUSTIN (Hamburg; Münster, Germany) .................................................................................................................. 3169

Clinical Value of Squamous Cell Carcinoma Antigen (SCCAg) in Anal Cancer – A Single-Center Retrospective Analysis. C. HENKENBERENS, H. TOKLU, C. TAMME, F. BRUNS (Hannover; Gehrden, Germany) .................................................................................................................. 3173

Expression of the Tumor-associated Mucin 1 Epitope Analyzed with the Humanized PankoMab-GEX™ Antibody in Malignant and Normal Tissues of the Head and Neck. I. WIEST, C. ALEXIOU, K. FRIESE, P. BETZ, J. TÜBEL, S. GOLETZ, D. DIAN, U. JESCHKE (Munich; Erlangen; Berlin, Germany) .................................................................................................................. 3179

Thyroid Hormones and Vitamin D in Patients with Breast Cancer with Mutations in BRCA1 or BRCA2 Genes. T. KOLBEN, T. HARY, L.M. HOLDT, T.M. SCHWARZ, C. GOESS, R. WUERSTLEIN, J. GALLWAS, B. TOOTH, T. WEISSENBACHER, U. JESCHKE, N. HARBECK, N. DITSCH (Munich; Heidelberg, Germany) .................................................................................................................. 3185

Sport in the Rehabilitation of Patients After Total Laryngectomy. J. BÜNZTEL, H. BÜNZTEL, R. MÜCKE, A. BESSER, O. MICKE (Nordhausen; Lemgo; Bielefeld, Germany) .................................................................................................................. 3191

Contents continued on the preceding page

Clinicopathological Features of Cases with Primary Breast Cancer not Identified by 18F-FDG-PET. T. FUJII, R. YAJIMA, M. TSUBOI, T. HIGUCHI, S. Oabayashi, H. TOKINIWA, R. NAGAOKA, D. TAKATA, J. HORIGUCHI, H. KUWANO (Gunma, Japan)...................................................................................................... 3019

Hepatic Resection for Liver Metastases from Cervical Cancer Is Safe and May Have Survival Benefit. N. BACALBASA, I. BADESCU, S. DIMA, I. POPESCU (Bucharest, Romania) .................................................. 3023

Effect of Sarcopenic Obesity on Outcomes of Living-Donor Liver Transplantation for Hepatocellular Carcinoma. S. ITOH, T. YOSHIZUMI, K. KIMURA, H. OKABE, N. HARIMOTO, T. IKEGAMI, H. UCHIYAMA, K. SHIRABE, A. NISHIE, Y. MAEHARA (Fukuoka, Japan) .................................................... 3029


Clinical Impact of Laparoscopy and Endoscopy Cooperative Surgery (LECS) on Gastric Submucoosal Tumor After its Standardization. S. KOMATSU, D. ICHIKAWA, T. KOSUGA, K. OKAMOTO, H. KONISHI, A. SHIOZAKI, H. FUJIWARA, O. DOHI, N. YAGI, E. OTSUJI (Kyoto; Gifu, Japan) ........................................ 3041

Ten-year Survivors After Contemporary Management of Advanced ‘Horseshoe’ Anterior Commissure Laryngeal Cancer. F. AMPIL, T. YOSHIZUMI, K. KIMURA, H. OKABE, N. HARIMOTO, T. IKEGAMI, H. UCHIYAMA, K. SHIRABE, A. NISHIE, Y. MAEHARA (Fukuoka; Ehime, Japan) .................................................... 3049

The Contribution of Dental Implants to Functional Artificial Restoration After Treatment of Oral Cancer. Y. KOBAYASHI, T. SUMIDA, A. ISHIKAWA, Y. MORI (Fukuoka; Ehime, Japan) .................................................... 3053

Prognostic Impact of EGFR Driver Mutations on Postoperative Disease Recurrence in Lung Adenocarcinoma. T. OKAMOTO, H. KITAHARA, S. SHIMAMATSU, M. KATSURA, K. TAKADA, T. FUJISHITA, Y. SUZUKI, Y. MORODOMI, T. TAGAWA, Y. MAEHARA (Fukuoka, Japan) .................................................... 3057

Distance from Primary Tumor Is the Strongest Predictor for Early Onset of Brain Metastases in Melanoma. E. GORKA, D. FABÓ, A. GÉZSI, K. CZIRBESZ, G. LISZKAY (Budapest, Hungary)................................................................. 3065

Potential Impact of the Overall Treatment Time on Outcomes after Whole-brain Irradiation with 10x3 Gy for Brain Metastases. D. RADES, S. JANSSSEN, T. VENINGA, S.E. SCHILD (Lübeck; Hannover, Germany; Tilburg, the Netherlands; Scottsdale, AZ, USA).............................................................................................................. 3071


Radiation Therapy Alone Provides Excellent Outcomes for Spinal Cord Compression from Vertebral Lymphoma. D. RADES, A.J. CONDE-MORENO, J. CACICEDO, B. ŠEGEDIN, V. RUDAT, S.E. SCHILD (Lübeck, Germany; Castellón; Barakaldo, Spain; Ljubljana, Republic of Slovenia; Al Khobar, Kingdom of Saudi Arabia; Scottsdale, AZ, USA).............................................................................................................. 3081

PROCEEDINGS OF THE 16TH INTERNATIONAL HAMBURG SYMPOSIUM ON TUMOR MARKERS, 19-21 October, 2014 (Hamburg, Germany)....................................................................................................................... 3085-3222


SOX2 and ALDH1 as Predictors of Operable Breast Cancer. H. SHIMA, G. KUTOMI, F. SATOMI, H. MAEDA, Y. HIROHASHI, T. HASEGAWA, M. MORI, T. TORIGOE, I. TAKEMASA (Sapporo, Japan) ....


Semiautomatic Whole-lesion Apparent Diffusion Coefficient Assessment for Early Prediction of Liver Tumor Response to Radioembolization. N. RATHMANN, J. BUDJAN, F. MARI, R. GRIMM, U. AT TENBERGER, M. KOSTRZEWA, M. SADICK, S.O. SCHOENBERG, S.J. DIEHL (Mannheim; Erlangen, Germany) ........

Late Rectal Toxicity from Image-guided Intensity Modulated Radiotherapy for Prostate Cancer. S. MAKI, Y. ITOH, S. KUBOTA, T. OKADA, R. NAKAHARA, J. ITO, M. KAWAMURA, T. KAMOMAE, S. NAGANAWA, Y. YOSHINO, M. GOTOH, M. IKEDA (Nagoya, Aichi, Japan) ...............................................


ABCG2 Overexpression Confers Poor Outcomes in Hepatocellular Carcinoma of Elderly Patients. Y.-L. CHEN, P.-M. CHEN, P.-Y. LIN, Y.-T. HSIAU, P.-Y. CHU (Kaohsiung; Changhua; New Taipei City; Tainan, Taiwan, ROC) ........................................

A Total Radiation Dose of 70 Gy Is Required After Macroscopically Incomplete Resection of Squamous Cell Carcinoma of the Head and Neck. D. RADES, S. JANSEN, A. BAJROVIC, P. STROJAN, S.E. SCHILD (Lübeck; Hannover; Hamburg, Germany; Ljubljana, Republic of Slovenia; Scottsdale, AZ, USA) ........................................................................

The Value of Lymph Node Dissection in the Surgery of Colorectal Cancer Liver Metastases. A. BRADATSCH, P. KORNPRAT, H. BACHER, H. CERVENKA, J. HAYBAECK, H.-J. MISCHINGER (Graz, Austria) ........................................................................

Efficacy of Ethinylestradiol Re-challenge for Metastatic Castration-resistant Prostate Cancer. T. ONISHI, T. SHIBAHARA, S. MASUI, Y. SUGINO, S. HIGASHI, T. SASAKI (Ise; Tsu, Japan) ...................................

Does the Rectus Sheath Block Analgesia Reduce the Inflammatory Response Biomarkers’ IL-1ra, IL-6, IL-8, IL-10 and IL-1β Concentrations Following Surgery? A Randomized Clinical Trial of Patients with Cancer and Benign Disease. M. PURDY, M. KOKKI, M. ANT TILA, S. ASPINEN, P. JUVONEN, R. KORHONEN, T. SELANDER, H. KOKKI, M. ES KELINEN (Kuopio, Finland) ...........................................................................................................
Synthesis of tris(quinoline)monochloroplatinum(II) Chloride and its Activity Alone and in Combination with Capsaicin and Curcumin in Human Ovarian Cancer Cell Lines. L. ARZUMAN, P. BEALE, J.Q. YU, F. HUQ (Lidcombe; Concord, NSW, Australia) ................................................................................................................... 2809

Histone Deacetylase-1-mediated Suppression of FAS in Chemoresistant Ovarian Cancer Cells. E. CACAN (Tokat, Turkey) ........................................................................................................................................................ 2819

Clinical Studies

Bendamustin–Rituximab Combination Is a Safe and Effective, Ambulatory Treatment for Elderly Patients with Chronic Lymphocytic Leukemia: Retrospective Real-world Analysis by Age from a German Registry and Review of the Literature. U.R. KLEEBERG, H. LINDE, G. GÜNTHER, H.-W. TESSEN, M. KERSTING (Hamburg; Goslar; Sarstedt, Germany) ................................................................................................................ 2827

Expression of Estrogen Receptors in Relation to Hormone Levels and the Nottingham Prognostic Index. M. FAHLÉN, H. ZHANG, L. LÖFGREN, B. MASIRONI, E. VON SCHOULTZ, B. VON SCHOULTZ, L. SAHLIN (Stockholm, Sweden; Chongqing, PR China) ................................................................................................................................................ 2839

Self-reported Symptoms to Monitor Recurrent Head and Neck Cancer—Analysis of 1,678 Cases. M.E. BOYSEN, U.K. ZÄTTERSTRÖM, J.F. EVENSEN (Oslo, Norway) ........................................................................................................................................................................ 2849

Pancreatic-type Acinar Cell Carcinoma of the Stomach Included in Multiple Primary Carcinomas. Y. YONENAGA, M. KUROSAWA, M. MISE, M. YAMAGISHI, S. HIGASHIDE (Nagahama, Japan) ........................................................................................................................................................................ 2855


Diagnostic and Prognostic Value of ProEx C and GLUT1 in Melanocytic Lesions. S. YAN, B.N. COFFING, Z. LI, H. XIE, J.B. BRENNICK, H.A. BEG, H.M. FROEHlich, W.A. WELLS (Lebanon; Hanover, NH, USA) ........................................................................................................................................................................ 2871

Phase II Trial of Erlotinib in Elderly Patients with Previously Treated Non-small Cell Lung Cancer: Results of the Lung Oncology Group in Kyushu (LOGiK-0802). K. YAMADA, K. AZUMA, M. TAKESHITA, J. UCHINO, C. NISHIDA, T. SUETSUGU, A. KONDO, T. HARADA, H. EIDA, J. KISHIMOTO, G. ERIGUCHI, K. TAKAYAMA, Y. NAKANISHI, K. SUGIO (Fukuoka; Kagoshima; Nagasaki; Kumamoto; Oita, Japan) ........................................................................................................................................................................ 2881

Acute Renal Failure Associated with Lenalidomide Treatment in Multiple Myeloma: A Rare Occurrence? N. KREINIZ, A. KHATEEB, S. GINO-MOOR, A. POLLIAcK, T. TADMOR (Haifa; Jerusalem, Israel) ........ 2889


Total Thyroidectomy Versus Lobectomy for the Treatment of Follicular Thyroid Microcarcinoma. U.C. MEGWALU, R.W. GREEN (Stanford, CA; New York, NY, USA) ........................................................................................................................................................................ 2899

Survival Outcomes in Early Stage Laryngeal Cancer. U.C. MEGWALU, H. PANOSSIAN (Stanford, CA; New York, NY, USA) ........................................................................................................................................................................ 2903

Heterogeneity of Vascular Endothelial Growth Factor Receptors 1, 2, 3 in Primary Human Colorectal Carcinoma. A. NASIR, L. O’NEILL REISING, D.M. NEDDERMAN, A.D. FULFORD, M.T. UHLIK, L.E. BENJAMIN, A.E. SCHADE, T.R. HOLZER (Indianapolis, IN, USA) ...............................................................

Identification of ESE1 as a β-Catenin Binding Protein. X. YANG, S.-H. LEE (College Park, MD, USA) ......


Expression Pattern of Matrix Metalloproteinase 20 (MMP20) in Human Tumors. D. KRAUS, J. RECKENBEIL, S. PERNER, J. WINTER, R. PROBSTMEIER (Bonn; Luebeck; Borstel; Bonn, Germany)....................................

Anticancer and Immunomodulatory Effects of Lactobacillus plantarum LS/07, Inulin and Melatonin in NMU-induced Rat Model of Breast Cancer. M. KASSAYOVÁ, N. BOBROV, L. STROJNÝ, P. ORENDAŠ, V. DEMAČKOVÁ, R. JENDŽELOVSKÝ, P. KUBATKA, T. KISKOVÁ, P. KRŮŽLIK, M. ADAMKOV, A. BOMBA, P. FEDOROČKO (Košice; Martin, Slovak Republic; Brno, Czech Republic) ...................................

The Difference in Bronchial Patency Between the Sweet and Modified Overfolt Methods at a Deep Site: Current Strategies Are Based on Previous Knowledge. Y. NAKAJIMA, Y. IIJIMA, H. URAMOTO (Saitama; Uchinada, Japan) ....................................................................................................................................................


Detection and Characterization of Flat Aberrant Crypt Foci (Flat ACF) in the Novel A/J Min/+ Mouse. M. SØDRING, G. GUNNES, J.E. PAULSEN (Oslo, Norway)..................................................................................

Antiproliferative Effects of Various Furanoacridones Isolated from Ruta graveolens on Human Breast Cancer Cell Lines. Z. SCHELZ, I. OCOSVSZKI, N. BÓZSITY, J. HOHMANN, I. ZUPKÓ (Szeged, Hungary) ......

Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin Mesylate. K. BRAUTIGAM, K. MITZLAFF, L. UEBEL, F. KÖSTER, S. POLACK, M. PERVAN, G. STEINERT, A. RODY, C. LIEDTKE (Lübeck; Frankfurt am Main, Germany) ....................................................................................................


Novel Midkine Inhibitor iMDK Inhibits Tumor Growth and Angiogenesis in Oral Squamous Cell Carcinoma. M. MASUI, T. OKUI, T. SHIMO, K. TAKABATAKE, T. FUKAZAWA, K. MATSUMOTO, N. KURIO, S. IBARAGI, Y. NAOMOTO, H. NAGATSUKA, A. SASAKI (Okayama, Japan)................................................

Effect of MPS1 Inhibition on Genotoxic Stress Responses in Murine Tumour Cells. M. SUZUKI, T. YAMAMORI, H. YASUI, O. INANAMI (Sapporo, Japan)..........................................................

Estrogen Enhances Malignant Phenotypes in Human Salivary Adenoid Cystic Carcinoma Cells. T. SUMIDA, A. ISHIKAWA, Y. KAMATA, H. NAKANO, T. YAMADA, Y. MORI (Fukuoka; Ehime, Japan) ......................

Targeted Therapies in HPV-positive and -negative HNSCC –Alteration of EGFR and VEGFR-2 Expression In Vitro. B. KRAMER, C. HOCK, R. BIRK, A. SAUTER, B.A. STUCK, K. HÖRMANN, J.D. SCHULTZ, C. ADERHOLD (Mannheim; Essen, Germany)..................................................................................